PCSK9 inhibitors: A new improvement for health-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PCSK9 inhibitors: A new improvement for health

Published:2019-09 Issue:5 Volume:31 Page:241-243
ISSN:2529-9123
Container-title:Clínica e Investigación en Arteriosclerosis (English Edition)
language:en
Short-container-title:Clínica e Investigación en Arteriosclerosis (English Edition)

Author:

Perelló Camacho Eva

Publisher

Elsevier BV

Subject

General Medicine

Reference8 articles.

1. PCSK9 inhibitors in clinical practice: expectations and reality;Reiner;Atherosclerosis,2018

2. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? Estimates form a large single center;Hohenstein;Atheroscler Suppl,2017

3. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?;Schettler;Atheroscler Suppl,2017

4. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial;Moriarty;Eur Herat J,2016

5. PCSK9 inhibition in the management of familial hypercholesterolemia;Ogura;J Cardiol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP